健康長寿に挑むステロイドホルモンDHEAS 進化医学から謎に迫る

出版社： 大道学館
著者：
発行日： 2019-05-24
分野： 臨床医学：一般  >  薬物療法
ISBN： 9784924391796
電子書籍版： 2019-05-24 （初版第1刷）
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,860 円(税込)

購入する

商品紹介

ヒトと類人猿のみに大量に存在するDHEASの研究はようやく、そのベールががはがされ、全貌が明らかにされる時が来た。進化医学を基礎にDHEASの謎に迫る。

目次

  • 表紙
  • 推薦の言葉
  • はじめに
  • 目次
  • 第1章 副腎ステロイドホルモンの歴史
  • 1 トーマス・アジソンの洞察力
  • (1) アジソンの生い立ち
  • (2) ガイ病院での活躍
  • (3) アジソン病の発見
  • (4) アジソン病と多腺性自己免疫症候群
  • 2 フィリップ・S・ヘンチの慧眼
  • (1) ステロイド治療の黎明期
  • (2) ヘンチの慧眼
  • (3) ハンス・セリエのストレス学説と副腎
  • 3 ジョン・F・ケネディのアジソン病との戦い
  • 4 若い人へのメッセージ - アジソン、ヘンチとケネディから学ぶ事 -
  • (1) するどい観察眼と深い洞察力
  • (2) 医学教育
  • (3) 九州大学医学部の開学
  • 第2章 ステロイドホルモンの分類
  • 第3章 ステロイドホルモンの生合成と作用機構の全貌
  • 1 ステロイドホルモン生合成酵素シトクロームP450
  • (1) 副腎皮質ステロイドホルモンの生合成
  • (2) 副腎皮質の層構造と細胞分化
  • 2 ヒトに新しく発見されたバックドア経路
  • 3 先天性副腎過形成
  • (1) ポピュラーな病気 - 21水酸化酵素欠損症 -
  • (1) 病態
  • (2) 遺伝子変異と臨床病型の関係
  • (3) 成人発症の非古典型
  • (4) 何故ポピュラーな病気なのか
  • 4 転写因子と核内受容体
  • (1) ステロイドホルモンの作用発現
  • (2) ステロイドホルモン受容体の構造と種類
  • (3) ステロイドホルモン受容体は創薬開発のターゲット
  • (4) ストレスと核内受容体TINUR ( NURR1 )
  • (5) ステロイドホルモンの作用に重要なコレギュレーター
  • (1) ステロイドホルモンによる転写の促進と抑制のメカニズム
  • (2) 核内で転写が迅速に進むための機能的コンパートメント
  • (3) ARのAF - 1結合コアクチベーターANT - 1 ( PRPF6 )
  • 5 細胞膜受容体
  • 6 副腎・性腺のマスター転写因子Ad4BP / SF - 1
  • (1) マスター転写因子Ad4BP / SF - 1
  • (1) Ad4BP / SF - 1による解糖系の制御
  • (2) Ad4BP / SF - 1のリガンド
  • 第4章 転写因子病とコアクチベーター病
  • 1 転写因子病とは
  • 2 副腎と性分化は密接に関係する
  • 3 男が女になるアンドロゲン受容体異常症
  • 4 新しい疾患概念コアクチベーター病
  • 5 転写因子異常によるアジソン病
  • (1) DAX - 1異常症
  • (2) Ad4BP / SF - 1異常症
  • 6 厚生労働省の難病指定
  • 第5章 内分泌かく乱物質 ( 環境ホルモン )
  • 1 レイチェル・カーソンの警鐘
  • 2 内分泌かく乱物質への挑戦
  • (1) アンドロゲン受容体
  • (2) アロマターゼ
  • (3) Ad4BP / SF - 1
  • 3 何故多くの化学物質はエストロゲン作用をかく乱するのか
  • 4 今後の課題
  • 5 人類を滅亡から救うために
  • 第6章 歴史上の半陰陽の話題
  • 1 ギリシャ神話に始まる半陰陽
  • 2 半陰陽の分類
  • (1) 仮性半陰陽
  • (2) 真性半陰陽
  • 3 21水酸化酵素欠損症と女性仮性半陰陽
  • 4 アスリートと真性半陰陽
  • 5 教皇ジョアンナは女性仮性半陰陽だったのか
  • 第7章 新しい治療法の開発
  • 1 副腎再生とグルココルチコイドの副作用の対策
  • (1) 副腎クリーゼと副腎再生
  • (2) グルココルチコイドの副作用の対策
  • 2 前立腺に抑制作用を示すアンドロゲン受容体モデュレーター
  • (1) 加齢男性性腺機能低下症候群 ( LOH症候群 )
  • (2) 男性における女性ホルモン ( E2 ) の役割
  • (3) アンドロゲン受容体モデュレーター ( SARM ) の開発
  • (4) SARM開発の現状
  • 第8章 進化医学が拓くステロイドホルモンの最前線
  • 1 進化医学とは
  • (1) ダーウィンの進化論
  • (2) 進化医学
  • 2 ヤツメウナギからの進化 - 祖先ERとステロイドホルモン生合成・代謝酵素 -
  • (1) ステロイドホルモン受容体の進化
  • (2) ステロイドホルモン生合成と代謝酵素の進化
  • 第9章 進化医学からDHEASの謎に迫る
  • 1 DHEASの研究と取り組み
  • 2 霊長類のなかでヒトと類人猿のみに大量に存在するDHEAS
  • 3 ヒトにおけるDHEASの一生
  • 4 ヒトのライフヒストリーを通して重要なDHEAS
  • (1) 胎児期
  • (2) アドレナーキ
  • (1) アドレナーキの引き金は何か
  • (2) 網状帯におけるDHEAS生合成メカニズム
  • (3) アドレナーキにおけるDHEASの生理学的意義
  • (イ) 脳の発達
  • (ロ) 成長と栄養
  • (ハ) 早発アドレナーキ ( premature adrenarche : PA )
  • (a) H6PDH欠損症
  • (b) PAPSS2欠損症
  • (3) アドレノポーズ
  • (1) アルツハイマー型認知症
  • (イ) ヒトの脳におけるDHEAの生合成とアミロイドβ産生抑制
  • (a) ヒトの脳はDHEAを生合成する
  • (b) 酸化ストレスは新しい経路でDHEAを生合成する
  • (c) DHEAはAβの産生を抑制する
  • (ロ) DHEAとDHEASの脳における作用メカニズム
  • (ハ) DHEAの臨床介入試験
  • (2) 心血管疾患
  • (イ) DHEAの抗肥満作用と抗グルココルチコイド作用
  • (ロ) DHEAの心血管における作用メカニズム
  • (ハ) DHEAの臨床疫学エビデンス
  • (3) フレイル・サルコペニア
  • (4) 気分感情障害とうつ病
  • (5) 免疫機能の低下
  • (イ) 好中球の食作用の低下
  • (ロ) サイトカインの産生の変化
  • 5 DHEAとDHEASの作用機構
  • (1) イントラクリノロジー ( intracrinology )
  • (2) 核内受容体と細胞膜受容体
  • (1) 核内受容体
  • (2) 細胞膜受容体
  • (イ) GABAA受容体
  • (ロ) NMDA受容体
  • (ハ) シグマ1受容体
  • (ニ) TrKA受容体 ( チロシンキナーゼA受容体 )
  • (ホ) G蛋白型共役型受容体 ( GPCR )
  • (ヘ) G蛋白共役型エストロゲン受容体 ( GPER )
  • (ト) IGF - 1受容体
  • (3) DHEAとDHEAS受容体の展望
  • 第10章 超高齢社会とDHEAS
  • 1 健康長寿とDHEAS
  • (1) 寿命を決定する遺伝子とエピジェネティクス
  • (2) DHEAのシャペロン誘導とアンチエイジング
  • (1) TSPO ( トランスローケーター蛋白 )
  • (2) HSP90
  • (3) HSP70
  • (4) HSP47
  • (5) シグマ1受容体
  • (6) ANKRD13C
  • (3) コルチゾールのシャペロン誘導とストレス
  • (4) 血中DHEAS濃度に相関する遺伝子
  • (1) ジンクフィンガー蛋白 ( ZKSCAN5 )
  • (2) SULT2A1
  • (3) HHEX
  • (4) CYP2C9
  • (5) ARPCIA
  • (6) BCL2L11
  • (5) DHEASと長寿
  • (6) 栄養と長寿 - メタボリックシンドロームとリバースメタボリズム -
  • 2 DHEAの補充療法
  • 第11章 生活習慣病の予防
  • 1 先制医療 ( preemptive medicine )
  • 2 カルナヘルスサポート ( 合同会社 )
  • 3 チーム医療の重要性
  • おわりに
  • 用語と略語の説明
  • 参考文献
  • 著者プロフィール
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 副腎ステロイドホルモンの歴史

P.18 掲載の参考文献
1. 名和田新 (2005) 「ステロイド療法の科学史-臓器抽出から化学合成, そしてそれら」『総合臨床』第54巻7月号, 1951-1953頁.
 
2. ルチャーノ・ステルペローネ (2011) 『医学の歴史』小川煕訳, 原書房.
 
3. 井村裕夫 (1992) 『生命のメッセンジャーに魅せられた人びと, 内分泌学の潮流』羊土社.
 
4. 井村裕夫 (1995) 『医のフィリア-内科学におけるサイエンス・アート・ヒューマニティ』中山書房.
 
5. マイケル・ブリス (2012) 『ウィリアム・オスラー-ある臨床医の生涯』三枝小夜子訳, メディカルサイエンスインターナソナル.
 
6. 山本和隆 (2013) 『ケネデイの遺産-JFKとニュー・フロンティアの時代』志學社.
 
7. 飯沼和正, 菅野富夫 (2000) 『高峰譲吉の生涯-アドレナリン発見の真実』朝日新聞社.
 
8. 井林博 (1977) 「退官にあたって-大学卒後40年の回顧」『九州大学医学部同窓会誌 學士鍋』第63号, 419-424頁.
 
9. ウィリアム・オスラー (1983) 『平静の心-オスラー博士講演集』日野原重明, 仁木久恵訳, 医学書院.
 
10. 日野原重明 (1991) 『医学するこころ-オスラー博士の生涯』岩波書店
 
11. 名和田新 (1995) 「医療今昔物語-学説・診療の変遷-橋本病 橋本策博士を偲んで」『臨床科学』第31巻, 1567-1571頁.
 
12. 名和田新 (1993) 「橋本病記念講演会」『九州大学医学部同窓会誌 學士鍋』第86巻, 38-40頁.
 
13. Hashimoto H. Zur Kenntniss der Lymphomatosen Veranderung der Schilddruse (Sruma Lymphomatosen) Arch. Klin. Chir. 97 : 219-248, 1912
 
14. 山村雄一 (1987) 『医学と人間』クリニックマガジン.
 
15. 小野寺龍太 (2010) 『日露戦争時代のある医学との日記-小野寺直助が見た明治』弦書房.
 
16. 小野寺直助先生顕彰会 (1996) 『小野寺直助先生, 博愛, 創造の遺志』.
 
17. Shifrin A, History discovery of the adrenal glands The adrenal gland tumors 2014.
 
18. Pearce JMS Thomas Addison (1793-18609) J. Royal Society Medicine 97 : 297-300, 2004.
 
19. Levas K, Husebye E. S. Addison's disease Lancet 365 : 2058-2061, 2005. Thomas Addison 1793-1860, Endocrine Today 2014.
 
20. Addison T. Anemia-disease of the suprarenal capsules London Med. Gazzete 43 : 517-518, 1949.
 
21. Addison T Chronic suprarenal insufficiency, usually due to tuberculosis of suprarenal capsule. Lond. Med. Gazette 43 : 517-518, 1849.
 
22. Addison T. On the constitutional and local effects of disease of the suprarenal capsule. In a collection of the published writings of the late Thomas Addison MD. London New Sydenham society, 1868.
 
23. On the constitutional and local effects of disease of the suprarenal capsules/by Thomas Addison Classics of Medical Library : Special edition 1980.
 
24. Lioyd M. Philip Showalter Hench 1896-1965. Rheumatology 41 : 582-584, 2002
 
25. Joshi V. R. Pioneers in Rheumatology, PS Hench. J. Associat. Physic. India 62 : 444-445, 2014
 
26. Moran LA Nobel Laureates : Edward Kendall, Tadus Reichstein and Philip Hench. The Nobel Prize in Physiology or Medicine 1950 Sandwalk, Strolling with a skeptical biochemist 2008.
 
27. Szabo S. et. al. The legacy of Hans Selye and the origin of stress research. : a retrospective 75 years after his landmark brief letter to the editor of nature. Stress 15 : 472-478, 2012.
 
28. Gabriel G. Hans Selye : The discovery of stress. Brain connection brainhq.com. 2013
 
29. Mandel LR. Endocrine and autoimmune aspects of the health history of John F. kennedy. Ann. Intern. Med. 151 : 350-354, 2009.
 
30. Polyglandular deficiency syndrome The Merk Mannal 2014.
 

第2章 ステロイドホルモンの分類

P.45 掲載の参考文献
1. 高橋元, 光多長温 (2012) 『超高齢社会』中央経済社.
 
2. 名和田新 (2013) 「高齢化社会における統合医療の重要性」『きんむ医』第164号, 1-2頁.
 
3. 井村裕夫 (2012) 『日本の未来を拓く医療-治療医学から先制医療へ』診断と治療社.
 
4. 竹田亮祐, 宮森勇, 山村博 (2009) 『生命への鍵ステロイド-その研究に貢献した生化学者と臨床家たち』前田書店.
 
5. 高橋知義, 堀内昭 (2010) 『ステロイドの化学』研成社.
 
6. Mackenzie S. et. al. Chemical Fossils : The geological fate of steroids. Science 217 : 491-504, 1982.
 
7. Higuchi, K., Nawata, H., Ibayashi, H. et. al, Prolactin has a direct effect on adrenal androgen secretion J. Clin. Endocrinol. Metab. 59 : 714-718, 1984.
 

第3章 ステロイドホルモンの生合成と作用機構の全貌

P.48 掲載の参考文献
1. 大村恒雄, 石村巽, 藤井義明 (2009) 『P450の分子生物学-第2版』講談社.
 
2. Stewart PM., Krone NP. The adrenal cortex 479-544, Textbook of Endocrinology.
 
3. Willams Textbook of Endocrinology 12th Edition Elsevier Sanders The adrenal cortex 499-544, 2011.
 
4. Higashijima, M., Nawata, H., Kato, K., Ibayashi, H. Studies on lipoprotein and adrenal steroidogenesis : I Roles of low density liporpotein-and high density lipoprotein-chlesterol in cultured human adrenocortical cells Endocrinol. Jpn. 34 : 635-645, 1987.
 
5. 名和田新 (2014) 「Cushing症候群-内分泌疾患」『内科学書』第8版 Vol.5, 156-163頁, 中山書店.
 
6. Sakai Y., Yanase T., Nawata H. et. al. In-vitro evidence for the regulation of 17,20-lyase Activity by cytochrome b5 in adrenocortical adenomas from patients with Cushing's syndrome. Clin. Endocrinol. 40 : 205-209, 1994.
 
7. Sakai Y., Yanase T. Nawata H. et. al. High expression of cytochrome b5 in adrenocortical adenomas from patients with Cushing's syndrome associated with high secretion of adrenal androgen. J. Clin. Endocrinol. Metab. 76 : 1286-1290, 1993.
 
8. Sakai Y., Yanase T., Nawata H. et. al. Mechanism of abnormal production of adrenal androgen in patients with adrenocortical adenomas and carcinomas. J. Clin. Endocrinol. Metab. 78 : 36-40, 1994.
 
9. Yanase T., Sasano H., Nawata H. et. al. Immunohistochemical study of cytochrome b5 in human adrenal gland and in adrenocortical adenomas from patients with Cushing's syndrome. Endocrine J. 45 : 89-95, 1998.
 
10. Okamoto M., Takemori H. Differentiation and zonation of the adrenal cortex. Curr Opin. Endocrinol. Diab. 7 : 122-127, 2000.
 
11. Mitani F., Mukai K., Ishimura Y. et. al. The undifferentiated cell zone is a stem cell zone in adult rat adrenal cortex. Bochim. Biophys. Acta 1619 : 317-324, 2003.
 
12. Nishimoto K., Nakagawara K., Mukai K. Adrenocortical zonation in humans under normal and pathological conditions. J. Clin. Endocrinol. Metab. 95 : 2296-2305, 2010.
 
13. 名和田新 (1999) 平成10年度特定疾患調査研究費補助金「内分泌疾患調査研究班-副腎ホルモン産生異常症」研究報告書.
 
14. Takayayagi R., Miura K., Nawata H., et. al. Epiologic study of adrenal disorders in Japan. Biomed. Pharmacother. 54 (Suppl. 1) : 164-168, 2000.
 
15. Auchus RJ. The backdoor pathway to dihydrotestosterone. Trends Endocrinol. Metab. 15 : 432-438, 2004.
PubMed
16. Fluck CE., Tajima T., Millar WL. et. al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Altley-Bixler syndrome. Nature Genet. 36 : 228-230, 2004.
 
17. Fukami M., Nishimura G. Ogata T. et. al. Cytochrome P450 oxidoreductase deficiency : Identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patient. J. Clin. Endocrinol. Metab. 94 : 1723-1731, 2009.
 
18. Fukami M., Homma K., Ogata T. et. al. Backdoor pathway for dihydrotestosterone biosynthesis : implications for normal and abnormal human sex development. Developmental Dynamics 242 : 320-329, 2013.
 
19. Kamrath C., Hochberg Z., Wudy SA. Increased activation of the alternative "backdoor" pathway in patients with 21-hydrooxylase deficiency : evidence from urinary steroid hormone analysis. J. Clin. Endocrinol. Metab. 97 : E367-E375, 2012.
PubMed
20. Ishimoto H., Jaffe RB. Development and function of the human fetal adrenal cortex : a key component in the feto-placenta unit. Endocr. Rev. 32 : 317-355, 2011.
PubMed
21. Kaludjerovic J. Ward WE. The interplay between estrogen and fetal adrenal cortex. J. Nutr. Metab. 2012 : 837-901, 2012.
 
22. 名和田新 (1998) 「宿題報告：転写調節因子の臨床」『日本内科学会雑誌』第87巻, 1692-1705頁.
 
23. 名和田新 (2003) 「会頭演説 : 21世紀の内分泌代謝学の展望-予防医学から先端医療まで」『日本内科学会雑誌』第92巻, 1610-1622頁.
 
24. 名和田新 (2013) 「ステロイドの歴史」宮坂信之編著『ポケットサイズのステロイド診療マニュアル』新興医学者社, 2-10頁.
 
25. 名和田新, 柳瀬敏彦, 阿部泰二郎他 (2008) 「ステロイド受容体のスーパーファミリーの分類と薬理」『日本臨床』第66巻1号, 9-15頁.
 
26. 阿部泰二郎, 柳瀬敏彦, 名和田新他 (2006) 「ステロイドの作用機序-最新の話題」『呼吸と循環』第54巻, 277-287頁.
 
27. 名和田新, 牟田和男 (2015) 「経口ステロイドと吸入ステロイド薬の基礎知識」『日本胸部臨床』第74巻第4号, 370-379頁.
 
28. Okabe T, Takayanagi R., Nawata H. cDNA cloning of a NGF 1-B/nurr-77 related transcription factor from an apoptotic human T cell line. J. Immunol. 154 : 3871-3879, 1995.
 
29. Okabe T., Takayanagi R., Nawata H. et. al. Nurr 77, a member of the steroid receptor superfamily, antagonizes negative feedback of ACTH synthesis and secretion by glucocorticoid in pituitary corticotroph cells. J. Endocrinol. 156 : 169-175, 1998.
 
30. Chen G., Nomura M., Nawata H. Modulation of androgen receptor transactivation by FoxoH1 : A newly identified androgen receptor corepressor. J. Biol. Chem. 280 : 36355-36363, 2005.
PubMed
31. Tomura A., Goto K., Nawata H., et. al. The subnuclear three-dimentional image analysis of androgen receptor fused to green fluorescence protein. J. Biol. Chem. 276 : 28359-28401, 2001.
 
32. Zhao Y., Goto K., Nawata H. et. al. Activation function-1 domain of androgen receptor contributes to the interaction between subcellular splicing factor compartment and nuclear receptor compartment. J. Biol. Chem. 277 : 30031-30039, 2002.
 
33. Goto K., Zhao Y., Nawata H. et. al. Activation function-1 domain of androgen receptor contributes the interaction between two distinct sets of subnuclear compartments. J. Steroid. Biochem. Molec. 85 : 201-208, 2003.
 
34. Fan S., Goto k., Nawata H. et. al. Identification of the functional domains of ANT-1, a novel coactivator of the androgen receptor. Biochem. Biophys. Res. Commun. 341 : 192-201, 2006.
 
35. Norman A. Mizwicki M., Norman D. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat. Rev. Drug. Discov. 3 : 27-41, 2004.
 
36. Zhu Y. et. al. Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes Proc. Natl. Acad. Sci. USA. 100 : 2231-2236, 2003.
 
37. Zhu Y., Bond J., Thomas P. Identification, classification, and partial characterization of genes in humans and other vertebrates homologus to a fish membrane progestin receptor. Proc. Natl. Acad. Sci. USA. 100 : 2237-2242, 2003.
 
38. Morohashi K, Honda S., Omura T. A common trans-acting factor, Ad4-binding protein of steroidogenic P-450s. J. Biol. Chem. 267 : 17913-17919, 1992.
PubMed
39. Morohashi K., et. al. Activation of CCYP11A and CYP11B gene promoters by the steroidogenic cell-specific transcription factor, Ad4BP. Mol. Endocrinol. 7 : 1196-1204, 1993.
 
40. Nomura M.. Nawata H., Morohashi K. et. al. An E box element is required for the expression of ad 4 bp gene. a mammalian homologue of ftz-f1 gene. which is essential for adrenal and gonadal development. J. Biol. Chem. 270 : 7453-7461, 1995.
 
41. Nomura M., Nawata H., Morohashi K. Autoregulatory loop in the regulation of the mammalian fiz-f1 gene. J. Biol. Chem, 271 : 8243-8249, 1996.
 
42. Oba K., Yanase T., Nawata H. et. al. Structural characterization of human Ad4BP (SF-1) gene. Biochem. Biophy. Res. Commun. 226 : 261-267, 1996.
 
43. Baba T., Otake H., Morohashi K. Glycolytic genes are targets of the nuclear receptor Ad4BP/SF-1. Nature Commun. 14 : 3634-3647, 2014.
 
44. Sablin EP., Blind RD., Ingraham HA. et. al. Structure of SF-1 bound by different phospholipids : Evidence for regulatory ligands. Mol. Endocrinol. 23 : 25-34, 2009
 
45. Blind RD., Suzawa M., Ingraham HA. Direct modification and a complex by the inositol lipid kinase IPMK. Science Signaling 5 : 1-9, 2012
 
46. Nimkarn S., New I. Maria. 21-hydoroxylase-deficient congenital adrenal hyperplasia. Gene Review 2013.
 
47. Nimkarn S., New I. Maria. Congenital adrenal hyperplasia due to 21-hydorxylase deficiency. A paradigm for prenatal diagnosis and treatment. Annals. New York Acad. Sci.1192 : 5 11. 2010
 
48. Maria I. New. Nonclassical 21-hydroylase deficiency. e-book, J. Clin.Endocrinol. Metab. 2013
 
49. 名和田新 (1992) 「成人多毛症」『日本内科学会雑誌』第81巻, 47-51頁.
 
50. Arlt W., Willis DS., Ross RJ. Congenital adrenal hyperplasia adult study executive (CaHASE) J. Clin.Endocrino. Metab. 95 : 5110-5121, 2010.
 

第4章 転写因子病とコアクチベーター病

P.82 掲載の参考文献
1. 名和田新 (1998) 「宿題報告 : 転写調節因子の臨床」『日本内科学会雑誌』第87巻9号, 1692-1705頁.
 
2. 岡田靖, 名和田新, 井林博他 (1985) 「Glucocorticoid受容体異常症に併発したCushing病のl例」『日本内科学会雑誌』第74巻5号, 611-617頁.
 
3. Nawata H., Sekiya K., Ibayashi H et. al. Decreased DNA binding of glucocorticoid-receptor complex in cultured skin fibroblast from a patient with the glucocorticoid resistance syndrome. J. Clin. Endocrinol. Meteb. 65 : 21 9-226. 1987
 
4. 柳瀬敏彦 (2000) 「副腎-性腺分化の分子機構とその異常」『現代医療』第32巻, 1657-1661頁
 
5. 名和田新 (2007) 「内分泌代謝疾患における転写因子 (核内受容体) とコレギュレーターの展開」『最新医学』第62巻10号, 22902294頁
 
6. Nawata H., Takayanagi R., Yanase T., et. al. Abnormalities of sex differentiation. Horm Res. 46 : 15-19, 1996
 
7. Nakao R., Haji M., Nawata H., et. al. A single amino acid substitution (Met786-Val) in the steroid binding domain of human androgen receptor leads to complete androgen insensitivity syndrome. J. Clin. Endocrinol. Metab. 74 : 1152-1157, 1992.
 
8. Nakao R., Yanase T., Nawata H., et. al. A single amino acid substitution (Gly743-Val) in the steroid binding domain of human androgen receptor in Reifenstein syndrome. J. Clin. Endocrinol. Metab. 77 : 103-107, 1993.
 
9. Hasegawa Y., Imasaki K., Nawata H. et. al. Incomplete androgen insensitivity associated with a thermolabile androgen receptor. Endocrine J. 41 : 31-35, 1994.
 
10. Imasaki K., Hasegawa T., Nawata H., et. al. Single amino acid substitution (840Arg-His) in the hormone binding domain of the androgen receptor. Eur. J Endocrinol. 130 : 569-574, 1994.
 
11. Imasaki K., Okabe T., Nawata H. Premature termination (777Glu-stop) in the hormone-binding domain of the androgen receptor in a patient with receptor negative form of complete androgen insensitivity syndrome. Endocrine J. 42 : 643-648, 1995.
 
12. Imasaki K., Okabe T., Nawata H. et. al. Androgen insensitivity syndrome in the DNA-binding domain of the androgen receptor. Mol. Cell. Endocrinol. 120 : 15-24, 1996.
 
13. Imasaki K., Hasegawa T., Nawata H. et. al. Sporadic Reifenstein syndrome due to a de novo mutation (746Val-Met) of the androgen receptor. Clin. Pediatr. Endocrinol. 5 : 1-9, 1996.
 
14. Nawata H., Imasaki K., Nawata H. et. al. Androgen Insensitivity syndrome. Frontier in Endocrinology. Sexual differentiation and maturation. 17 : 107-117, 1996.
 
15. Isurugi k., Hasegawa F., Nawata H. et. al. Incomplete testicular feminization syndrome studies on androgen receptor (AR) function, AR gene analysis, and aromatase activities are puberty and long-term observations of clinical and hormonal features from infancy to puberty. Endocrine J. 43 : 557-564, 1996.
 
16. Adachi M., Takayanagi R., Nawata H. et. al. Androgen-insensitivity syndrome as a possible coactivator disease. N. Engl. J. Med. 343 : 856-862, 2000.
 
17. Nawata H., Adachi M., Yanase T. Androgen insensitivity by coactivator abnormality. Clin. Pediatr. Endocrinol. 11 (Suppl 18) 17-24, 2002.
 
18. 名和田新 (2001) 「コアクチベーター病 新しい疾患概念としての転写因子病」『Medical Practice』第18巻4号, 682-684頁.
 
19. Saitoh M., Takayanagi R., Nawata H. et. al. The presence of both the amino-and carboxy-terminal domains in the androgen receptor is essential for the completion of a transcriptionally active form with coactivator and intranuclear compartmentalization common to the steroid hormone receptors : a three-dimensional imaging study. Molecular Endocrinol. 16 : 694-706, 2002.
 
20. 柳瀬俊彦, 加藤堅一, 名和田新, 井林博他 (1984) 「Addison病に性腺機能低下症ならびに甲状腺機能異常を合併した1例」『ホルモンと臨床』第32巻, 203-203頁.
 
21. 高柳諒一, 阿部泰二郎, 名和田新, 井林博他 (1992) 「性腺機能不全を合併した先天性副腎皮質髄質低形成の1例」『ホルモンと臨床』第40巻, 160-160頁.
 
22. 大江賢治, 古藤和浩, 名和田新他 (1993) 「低ゴナドトロピン性性腺機能低下症を合併したAddison病の1例」『日本内科学会雑誌』第82巻, 125頁.
 
23. Yanase T., Takayanagi R., Nawata H. et. al. New mutation of Dax-1 gene in two Japanese patients with X-linked adrenal hypoplasia and hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab. 81 : 530-535, 1996.
 
24. Hamaguchi K., Arikawa M., Nawata H. Novel mutation of the DAX-1 gene in a patient with X-linked adrenal hypoplasia congenital and hypogonadotropic hypogonadism. Am. J. Med. Genet. 76 : 62-66, 1998.
 
25. Ikuyama S., Mu Y-M, Nawata H. et. al. Expression of an orphan nuclear receptor DAX-1 in human pituitary adenomas. Clin. Endocrinol. 48 : 647-654, 1998.
 

第5章 内分泌かく乱物質 ( 環境ホルモン )

P.95 掲載の参考文献
1. 上遠恵子 (2013) 『レイチェル・カーソン-いのちと地球を愛した人』日本キリスト教団出版局.
 
2. レイチェル・カーソン (2001) 『沈黙の春』青樹築一訳, 新潮社.
 
3. シーア・コルボーン, ダイアン・ダマノスキ, ジョン・ピーターソン・マイヤーズ (1997)『奪われし未来』翔泳社.
 
4. シーア・コルボーン, ダイアン・ダマノスキ, ジョン・ピーターソン・マイヤーズ (2001)『奪われし未来 (増補改訂版) 』翔泳社.
 
5. 名和田新 (2000) 『岩波講座 現代医学の基礎-内分泌撹乱物質』岩波書店.
 
6. 名和田新(1999) 「核内受容体・共役因子と内分泌かく乱物質」戦略的創造研究推進事業, 『平成10年度採択研究課題研究終了報告書-内分泌かく乱物質』303-380頁.
 
7. Nawata H., Goto K., Morinaga H. et. al Molecular mechanism underlying the action of environmental endocrine-disrupting chemicals. Environmental Science 9 : 57-70, 2002.
 
8. Tomura A., Goto K., Nawata H., et. al. The subnuclear three-dimentional image analysis of androgen receptor fused to green fluorescence protein. J. Biol. Chem. 276 : 28395-28401, 2001.
 
9. Nishi Y., Yanase T., Nawata H. et. al. Establishment and characterization of a steroidogenic human granulosa-like tumor cell line, KGN, that expresses functional follicle-stimulating hormone receptor. Endocrinology 142 : 437-445,2001.
 
10. Ohno K., Yanase T., Nawata H. et. al. A nonradioactive method for measuring aromatase activity using a human ovarian granulosa-like tumor cell line and an estrone ELISA. Toxicol. Sci. 82 : 443-450, 2004.
 
11. Saitoh M., Yanase T., Nawata H. et. al Tributyltin or triphenyltin inhibits aromatase activity in the human granulosa-like tumor cell Line KGN. Biochem. Biophy. Res. commun. 289 : 198-204, 2001.
PubMed
12. Morinaga H., Yanase T., Nawata H., et. al A benzimidazole fungicide , benomyl and its metabolite. carbendazin, induce aromatase activity in a human ovarian granulosa-like cell line (KGN). Endocrinology 145 : 1860-1869, 2004.
 
13. Fan W., Yanase T., Nawata H., et. al. Atrazine-induced aromatase expression is SF-1-dependent : implication for endocrine disruption in wildlife and reproductive cancers in humans. Environmental Health Perspectives 115 : 720-727, 2007.
 
14. Fan W., Yanase T., Nawata H., et. al. Herbicide atrazine activates SF-1 direct affinity and concomitant coactivators recruitments to induce aromatase expression via promotor 11. Biochem. Biophys. Res. Commun. 355 : 1012-1018, 2007.
 
15. Fukuda Y., Morinaga H., Nawata H., et. al. Transformation products of bisphenol A by A recombinant Trametes villosa laccase and their estrogenic activity. J. Chem. Technol. Biotechnol. 79 : 1212-1218, 2004.
 
16. Baker E. Michel Insights from the structure of estrogen receptor into the evolution of estrogens : im plications for endocrine disruption. Biochem. Pharmacol. 82 : 1-8, 2011.
 
17. Thornton J. Pandora's poison, chlorine, health and a new environmental strategy MIT Press Cambridge Massachusetts, London England second printing 2000
 
18. Alexandar M., Dunhill M., Wills MA. Geographic range did not confer resilience to extinction in terrestrial vertebrates at the end-Triassic crisis. Nature Commun. 6 : 7980, 2015
 
19. Ibhazehiebo K., Jwasaki, T., Koibuchi N, et. al. Disruption of thyroid hormone receptormediated transcription and thyroid hormone-induced Purkinje cell dendrite aroborization by polybrominated diphenyl ethers. Environmental Health Perspect. 119 : 168-175, 2011.
 
20. Diamanti-Kandaakis E., Bourguignon JP. Soto AM., et. al. Endocrine-disrupting chemicals : an Endocrine Society scientific statement. Endocr. Rev. 30 : 293-342, 2009
 

第6章 歴史上の半陰陽の話題

P.111 掲載の参考文献
1. 中野京子 (2012) 『名画の謎-ギリシャ神話篇』文芸春秋.
 
2. ドナ・W. クロス (2005) 『女教皇ヨハンナ』阪田由美子訳, 上・下巻, 草思社.
 
3. 塩野七生 (2003) 『愛の年代記』新潮社.
 
4. Delle Piane L., Rinaudo PF., Miller WI. 150 years of congenital adrenal hyperplasia : translation and commentary of De Crecchio's classic paper from 1865. Endocrinology 156 : 1210-1217, 2015.
 
5. Milller WL. A brief history of adrenal research, Steroidogenesis-the soul of the adrenal. Mol. Cell. Endocrinol. 371 : 5-14, 2013.
 
6. Inoue H., Nomura M., Nawata H., et. al. A rare case of 46,XX true hermaphroditism with hidden mosaicism with sex-determining region Y chromosome-bearing cells in the gonads. Internal Med. 37 : 467-479, 1998.
 
7. Stella Walsh facts. Encyclopedia of women biography.
 
8. Du Wikipedia Maddalene Ventura con il marito e il figlio.
 
9. New MI. President address Pope Joan : A recognizable syndrome. J. Clin. Endocrinol. Metab. 76 : 3-13, 1993.
 
10. New MI. Ancient history of congenital adrenal hyperplasia. Endocr. Dev. Basel Kager 20 : 202-211, 2011.
 

第7章 新しい治療法の開発

P.122 掲載の参考文献
1. 名和田新 (2008) 「副腎不全：診断と治療の進歩-副腎不全の診断と治療の進歩と展望」『日本内科学会誌』第97巻, 699-701頁.
 
2. 柳瀬敏彦, 田中智子 (2009) 「ステロイド産生細胞再生研究の現状」『日本生殖内分泌学会雑誌』第14巻, 51-53頁.
 
3. Gondo S., Yanase T., Nawata H., et. al. SF-1/Ad4BP transforms primary long-term cultured bone marrow cells into ACTH-responsive steroidogenic cells. Gene to Cells. 9 : 1239-1247, 2004.
 
4. Tanaka T., Gondo S. Yanase T., Nawata H. et. al. Steroidogenic factor 1/adrenal 4 binding protein transforms human bone marrow mesenchymal cells into steroidogenic cells. J. Mol. Endocrinol. 39 : 343-350, 2007.
 
5. Gondo S., Okabe T., Yanase T., Nawata H., et. al. Adipose tissue-derived and bone marrow-derived mesenchymal cells develop into different lineage of steroidogenic cells by forced expression of steroidogenic factor 1. Endocrinology 149 : 4717-4725, 2008.
 
6. Nawata H., Soen S., Seino Y., et. al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for bone and mineral research J. Bone Mine. Metab. 23 : 105-109, 2005.
 
7. Suzuki Y., Nawata H., Tanaka Y. et. al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese society for Bone and Mineral research : 2014 update. J. Bone Miner. Metab. 32 : 337-350, 2014.
 
8. Wang C., Nieshlag E., Swerdloff R., et. al. Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA. ISSAM, EAU and ASA recommendations. Europ. J. Endocrinol. 159 : 507-514, 2008.
 
9. Morishima A., Grumbach MM., Qin K., et. al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J. Clin. Endocrinol. Metab. 80 : 3689-3698, 1995.
 
10. Carani C., Qin K., Simpson ER. Effect of testosterone and estradiol in a man with aromatase deficiency. New Engl. J. Med. 337 : 91-95, 1997.
 
11. Herrmann BL., Saller B., Broecker M., et. al. Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19Gene. J. Clin. Endocrinol. Metab. 87 : 5476-5484, 2002.
 
12. Maffei L., Murata Y., Rochira V., Carani., et. al. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene : Effect of testosterone, alendronate and estradiol treatment. J. Clin. Endocrinol. Metabol. 89 : 61-70, 2004.
 
13. Maffei L., Rochira V., Carani C., et. al. A novel compound heterozygous mutation of the aromatase gene in an adult man : reinforced evidence on the relationship between congenital oestrogen deficiency, adiposity and the metabolic syndrome. Clin. Endocrinol. 67 : 218-224, 2007.
 
14. Fan W., Yanase T., Nawata H., et. al. Androgen receptor null male mice develop late-onset obesity due to decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes 54 : 1000-1008, 2005.
 
15. Min L., Yanase T., Nawata H. et. al. A novel synthetic androgen receptor ligand, S42, works as a selective androgen receptor modulator possesses metabolic effects with little impact on the prostate. Endocrinology 150 : 5606-5616, 2009.
 
16. Ferre P., Foufelle F. SREBP-1c transcription factor and lipid homeostasis : clinical perspective. Hormone Res. 68 : 72-82, 2007.
PubMed
17. Bhasin S., Jasuja R. Selective androgen receptor modulates as function promoting therapies. Curr. Opin. Clin. Nutr. Metab. Care. 12 : 232-240, 2009.
PubMed
18. Dabs AS., et. al. Effects of enobosarm on muscle wasting and physical function in patients with cancer. a double-blind, randomized controlled phase 2 trial. Lancet Oncol. 14 : 335-345, 2013.
 
19. 柳瀬敏彦 (2014) 「選択的アンドローゲン受容体修飾薬開発の現況」『最新医学』第69巻5号, 977-984頁.
 

第8章 進化医学が拓くステロイドホルモンの最前線

P.135 掲載の参考文献
1. チャールズ・ダーウイン (2012) 『超訳 種の起源-生物はどのように進化してきたのか』夏目大訳, 技術評論社.
 
2. Nesse RM., Williams GC. (1996) 「Why we get sick?」Vintage Books New York.
 
3. 井村裕夫 (2000) 『人はなぜ病気になるのか-進化医学の視点』岩波書店.
 
4. 井村裕夫 (2008) 『進化医学からわかる肥満・糖尿病・寿命』岩波書店.
 
5. 井村裕夫 (2013) 『進化医学-人への進化が生んだ疾患』羊土社.
 
6. 太田博樹, 長谷川眞理子 (2013) 『ヒトは病気とともに進化した』勁草書房.
 
7. Thornton JW. Evolution of vertebrate steroid receptor from an ancestral estrogen receptor by ligand exploitation and serial genome expansion. Proc. Natl. Acad. Sci. 98 : 5671-5676, 2001.
PubMed
8. Thornton JW., Need E., Crews D. Resurrecting the ancestral steroid receptor : ancient origin of estrogen signaling. Science 301 : 1714-1717, 2003.
PubMed
9. Baker ME Co-evolution of steroidogenic and steroid-inactivating enzymes and adrenal and sex steroid receptors. Mol. Cell Endocrinol. 215 : 55-62, 2004.
PubMed
10. Baker ME. Origin and diversification of steroids : co-evolution of enzymes and nuclear receptors. Mol. Cell Endocrinol. 334 : 14-20, 2011.
PubMed
11. Baker ME. Insights from the structure of estrogen receptor into the evolution of estrogens : implication for endocrine disruption. Biochem. Pharmacol. 82 : 1-8, 2011.
PubMed
12. Eick GN., Thornton JW Evolution of steroid receptors from an estrogen-sensitive ancestral receptor. Mol. Cell. Endocrinol. 334 : 31-38, 2011.
PubMed
13. Kuiper GG., Carlsson B., Gradien K., et. al. Comparison of the ligand specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138 : 863-870, 1997.
 
14. Umetani M., Domoto H., Gormley AK., et. al. 27-hydroycholesterol is an endogenous SERM that inhibits the cardiovascular effect of estrogen Nature Med. 13 : 1185-1192, 2007.
 
15. Bjorkhein I. Do oxysterols control cholesterol homeostasis? J. Clin. Invest. 110 : 725-730, 2002.
 

第9章 進化医学からDHEASの謎に迫る

P.144 掲載の参考文献
1. Klinge C. M., Clark B. J., Prough R. A. Dehydroepiandrosterone research : past, current and future. Vitamins and Hormones, Chapter one 108 : 1-28, 2018. Elsevier Inc.
 
2. Simpson E., Santen R. J. Celebrating 75 years of oestradiol. J. Mol. Endocrinol. 55 : T1-20, 2015.
PubMed
3. Morales AJ., Nolan JJ., Yen SS., et. al. Effects of replacement dose of dehydroepi-androsterone in men and women of advancing age. J. Clin. Endocrinol. Metab. 78 : 1360-1367, 1994.
 
4. Yen SSC. Dehydroepiandrosterone sulfate and longevity : New clue for an old friend. Proc. Natl. Acad. Sci. 98 : 8167-8169, 2001.
 
5. Parker LN. Adrenal androgens in clinical medicine. Academic Press Inc. 1989.
 
6. レイ・サヘリアン (1997) 『DHEA奇跡のホルモン療法』大和洋子訳, 宝島社.
 
7. 矢内原巧 (1993) 『産婦人科医のDHA-Sの研究』医科学出版社.
 
8. Watson RR. DHEA in human health and aging. CRC Press Book 2012.
 
9. Hamberger C. Normal urinary excretion of neutral 17-ketosteroid with special reference to age and sex variations. Acta Endocrinol. 1 : 19, 1948.
 
10. Migeon C., Keller A., Shepard T., et. al. DHEA and androsterone levels in human plasma. effect of age and sex : day-to-day and dirnal variations. J. Clin. Endocrinol. Metab. 17 : 1051-1062, 1957.
 
11. Migeon C. Adrenal androgens in man. Am. J. Med. 53 : 606, 1972.
 
12. Yamaji T., Ibayashi H. Plasma DHEAS in normal and pathological conditions. J. Clin. Endocrinol. Metab. 29 : 273-278, 1969.
PubMed
13. Higuchi K., Nawata H., Ibayashi H., et. al. Prolactin has a direct effect on adrenal androgen secretion. J. Clin. Endocrinol. Metab. 59 : 714-718, 1984.
 
14. Nawata H., Higuchi K., Ibayashi H., et. al. Mechanism of dissociation of cortisol and adrenal androgen secretion after removal of adrenocortical adenoma in patients with Cushing's syndrome. Endocrinol. Jpn. 32 : 691-700, 1985.
 
15. Ohashi M., Kato K., Nawata H., Ibayashi H. Adrenocortical responsiveness to graded ACTH infusion in normal young and elder human subjects. Gerontology 32 : 43-51, 1986.
 
16. Ohashi M., Fujio N., Ibayashi H., et. al. Aging is without effect on the pituitary-adrenal axis in men. Gerontology 32 : 335-339, 1986.
 
17. Taniguchi S., Yanase T., Nawata H., et. al. The antiobesity effect of dehydroepi-androsterone in castrated obese or non-castrated obese Zucker male rats. Obesity Res. 3 : 639-643, 1995.
 
18. Taniguchi S., Yanase T., Nawata H., et. al. Dehydroepiandrostrone markedly inhibits the accumulation of cholesterol ester in mouse macrophage J774-1 cells. Atherosclerosis 126 : 143-154, 1996.
 
19. Nakashima N., Haji M., Nawata H., et. al. Effect of dehydroepiandrosterone on glucose uptake in cultured human fibroblasts. Metabolism 44 : 543-548, 1995.
 
20. Nakashima N., Haji M., Nawat H. et. al. Effect of dehydroepiandrosterone on glucose uptake in cultured rat myoblasts .Horm. Metab. Res. 27 : 491-494, 1995.
 
21. Yanase T., Fukahori M., Nawata H. et al. Serum dehydorepiandrosterone (DHEA) and DHEA-S in Alzheimer's disease and in cerebrovascular dementia. Endocrine J. 43 : 119-123, 1996.
 
22. Yanase T., Muta K., Nawata H. Serum concentrations of dehydroepiandrosterone sulfate (DHEA-S) in oldest old Japanese women correlate with cognitive activity rather than activities of daily living. Geriatr. Gerontol. Int. 6 : 194-198, 2006.
 
23. Okabe T., Haji M., Nawata H., et. al. Up-regulation of high-affinity dehydroepi-androsterone binding activity by dehydroepiandrosterone in activated T lymphocytes. J. Clin. Endocrinol. Metab. 80 : 2993-2996, 1995.
 
24. Ashida K., Goto K., Nawata H., et. al. Dehydroepiandrosterone negatively regulates the p38 mitogen-activated protein kinase pathway by a novel mitogen-activated protein kinase phosphatase. Biochem. Biophy. Acta 1728 : 84-94, 2005.
 
25. Watanabe T., Ashida K., Nawata H., et. al. Dehydroepiandrosterone-enhanced dual specificity protein phosphatase (DDSP) prevents diet-induced and genetic obesity. Biochem. Biophs. Res. Comm. 468 : 196-201, 2015.
 
26. Yamada Y., Sekihara H., Nawata H., et. al. Changes in serum sex hormone profiles after short-term low dose administration of dehydroepiandrosterone (DHEA) to young and elderly persons. Endocrine J. 54 : 153-162, 2007.
 
27. Nawata H., Tanaka S., Haji M., et. al. Aromatase in bone cell : association with osteoporosis in postmenopausal women. J. Steroid Biochem. Molec. Biol. 53 : 165-174, 1995.
 
28. Takayanagi R., Goto K., Nawata H., et. al. Dehydroepiandrosterone (DHEA) as a possible source for estrogen formation in bone cells : correlation between bone mineral density and serum DHEA-sulfate concentration in postmenopausal women and the presence of aromatase to be enhanced by 1,25-dihydroxyvitamin D3 in human osteoblasts. Mechanism. Aging Development 123 : 1107-1114, 2002.
 
29. Nawata H.,Yanase T., Goto K., et. al. Mechanism of action of anti-aging DHEA-S and the replacement of DHEA-S. Mechanism Ageing Development. 123 : 1101-1106, 2002.
 
30. Nawata H., Watanabe T., Yanase T. Sex hormone and neuroendocrine aspects of metabolic syndrome. Progress Brain Res. 182 : 175-188, 2010.
 
P.148 掲載の参考文献
1. Kroll J. Dehydroepiandrosterone, molecular chaperone and the epigenetics of primates longevity. Rejuvenation Res. 18 : 341-346, 2015.
PubMed
2. Cutler GBJ., Glenn M., Loriaux DL. et. al. Adrenarche : A survey of rodents, domestic animals and primates. Endocrinology 103 : 2112-2118, 1978.
 
P.149 掲載の参考文献
1. Nawata H., Yanase T., Goto K., et. al. Mechanism of action of anti-aging DHEA-S and the replacement of DHEA-S. Mechanism Ageing Development. 123 : 1101-1106, 2002.
 
2. Nawata H., Yanase T., Goto K., et. al. Adrenopause Hormone Res. 62 : 110-114, 2004.
 
P.152 掲載の参考文献
1. Marx CE., Jarskog F., Marrow AL., et. al. Neurosteroid modulation of embryonic neuronal survival in vitro following anoxia. Brain Res. 871 : 104-112, 2000.
 
2. Suzuki M., Wright LS., Svendsen CN., et. al. Mitotic and neurogenic effects of dehydro-epiandroasterone (DHEA) on human neural stem cell cultures derived from the fetal cortex. Proc. Natl. Acad. Sci. 101 : 3202-3207, 2004.
 
3. Pediaditakis I., Iliopoulos I., Gravanis A., et. al. Dehydroepiandrosterone : An ancestral ligand of neurotrophin receptors. Endocrinology 156 : 16-23, 2015.
 
4. Endocrine-adrenal development. Embryology 1-13, 2016.
 
5. Lupin SJ., MEwen BS., Heim G., et. al. Effects of stress throughout the lifespan on the brain, behavior and cognition. Nature Rev. Neurosci. 10 : 434-445, 2009.
 
P.155 掲載の参考文献
1. Rainey WE., Car BR., Sasano H., et. al. Dissecting human adrenal androgen production Trends in Endocrinol. Metab. 13 : 234-239, 2002.
 
2. Archus RJ., Rainey WE. Adrenarche-physiology, biochemistry and human disease. Clin Endocrinol. 60 : 288-296, 2004.
 
3. Rege J., Rainey WE. Themic Review. The steroid metabolome of adrenarche. J. Endocrinol. 214 : 133-143, 2012.
 
4. Hornsby PJ. Themic review. Adrenarche : a cell biological perspective J. Endocrinol. 214 : 113-119, 2012.
 
5. Ohashi M., Fujio N., Ibayashi H., et. al. Aging is without on the pituitary-adrenal axis in men. Gerontology 32 : 335-339, 1986.
 
6. Weber A., Clark AJL, Savage MO., et. al. Diminished adrenal androgen secretion in familial glucocorticoid deficiency implicates a significant role for ACTH in the induction of adrenarche. Clin. Endocrinol. 46 : 431-437, 1997.
 
7. Topor LS., Asai M., Majzoub JA., et. al. Cortisol stimulates secretion of dehydroepi-androsterone in human adrenocortical cells through inhibition of 3 β HSD2. J. Clin Endocrinol. Metab. 96 : 31-39, 2011.
 
P.158 掲載の参考文献
1. Campbell B. Feature article. Adrenarche and the evolution of human life history. Amer. J. Human Biol. 18 : 569-589, 2006.
 
2. Marcia S., Ponce DL. Neanderthal brain size at birth provides insights into the evolution of human history. Proc. Natl. Acad. Sci. 105 : 13764-13768, 2008.
 
3. 井村裕夫 (2016) 『健康長寿のための医学』岩波新書.
 
4. Dosenbach NU., Nardos SM., Schlagger BL., et. al. Prediction of individual brain maturity using fMRI. Science 329 : 1358-1361, 2010.
 
5. Laughlin GA, Barrett-Canner B. Sexual dimorphism in the influence of advanced aging on adrenal hormone levels : The Rancho Bernardo study. J. Clin Endocrinol. Metab. 85 : 3561-3568, 2000.
 
6. Guazzo EP., Kirkpatrick PJ., Herbert J., et. al. Cortisol, dehydroepiandrosterone (DHEA) and DHEA sulfate in the cerebrospinal fluid of man : relation to blood levels and the effect of age. J. Clin Endocrinol. Metab. 81 : 3951-3950, 1996.
 
7. Chen F., Knecht K., Reszka AA. Direct agonist/antagonist functions of dehydroepi-androsterone. Endocrinology. 146 : 4568-4567, 2005.
 
8. Bauliu EE., Robel P., Schumacher M. Neurosteroids. A new regulatory function in the nervous system. Humana Press 1999.
 
9. Twede V., Tartaglia AL., Bamber BA., et. al. The neurosteroids dehydroepiandrosterone sulfate and pregnenolone sulfate inhibit the UNC-49 GABA receptor through a common set of residues. Mol. Pharmacol. 72 : 1322-1329, 2007.
 
10. Strac DS., Jembrek MJ., Pericic D., et. al. Modulation of recombinant GABAA receptors by neurosteroid dehydorepiandrosterone sulfate. Pharmacology. 89 : 163-171, 2012.
 
11. Ong KK., Potau N., Dunger DB., et.al. Opposing influence of prenatal and postnatal weight gain on adrenarche in normal boys and girls. J. Clin. Endocrinol. Metab. 89 : 2647-2651, 2004.
PubMed
12. Nakashima N., Haji M., Nawata H., et. al. Effect of dehydroepiandrosterone on glucose uptake in cultured human fibroblasts. Metabolism. 44 : 543-548, 1995.
 
P.163 掲載の参考文献
1. Idkowiak J., Lovery GG., Arlt W., et. al. Premature adrenarche : novel lessons from early onset androgen excess. Eur. J. Endocrinol. 165 : 189-207, 2011.
 
2. Utrianen P., Loakso S., Voutilainen R. Premature adrenarche-a common condition with variable presentation. Horm. Res. Pediatr. 83 : 221-231, 2015.
 
P.167 掲載の参考文献
1. Maggio M., DeVita F., Paol CG., et. al. DHEA and cognitive function in the elderly. J. Steroid Biochem. Mol. Biol. 145 : 281-292, 2015.
 
2. Hampl R., Bicikova M. Neuroimmnomodulatory steroids in Alzheimer dementia. J. Steroid Biochem. Mol. Biol. 119 : 97-104, 2010.
PubMed
3. Ohara T., Doi Y., Kiyohara Y., et. al. Glucose tolerance status and risk of dementia in the Community. The Hisayama Study. Neurology 77 : 1126-1134, 2011.
 
4. Naylor JC., Hulette M., Marx CE., et. al. Cerebrospinal fluid dehyroepiandrosterone levels are correlated with brain dehydroepiandrosterne levels, elevated in Altzheimer's disease and related to neuropathological disease. J. Clin. Endocrinol. Metab. 93 : 3173-3178, 2008.
 
5. Weill-Engerer S., David JP., Baulieu EE., Akwa Y., et. al. Neurosteroid quantification in human brain regions : Comparison between Altzheimer's and nondementia patients. J. Clin. Endocrinol. Metab. 87 : 5138-5143, 2002.
 
6. Yanase T., Fukahori M., Nawata H., et. al. Serum dehydroepiandrosterne (DHEA) and DHEA-sulfate (DHEA-S) in Alzheimer's disease and in cerebrovascular dementia. Endocrine J. 43 : 119-123, 1996.
 
7. Aldred S., Mecocci P. Decreased dehydroepiandrosterone (DHEA) and deydroepi-androsterone sulfate (DHEAS) concentrations in plasma of Alzheimer disease (AD) patients. Arch. Ferontol. 51 : e16-e18, 2010.
 
8. Brown RC., Cascio C., Papadopoulos V. Pathways of neurosteroid biosynthesis in cell line from human brain : Regulation of dehydroepiandrosterone formation by oxidative stress and β-amyloidp eptide. J. Neurochem. 74 : 847-858, 2000.
 
9. Tamagno E., Guglielmotto M., Tabaton M. Dehydroepiandrosterone reduces expression and activity of BACE in NT2 neurons exposed to oxidative stress. Neurobiol. Disease. 14 : 291-304, 2003.
PubMed
10. Rammouz G., Lecanu L., Papadopoulos V. Oxidative stress-mediated brain dehydro-epiandrosterone (DHEA) formation in Alzheimer's disease diagnosis. Front. Endocrinol 2 : 69-87, 2011.
 
11. Guglielmotto M., Giliberto L., Tabaton M., et. al. Oxidative stress mediates the patho-genic effect of different Alzheimer's disease risk factor. Aging Neusci. 9 : 1-30, 2010.
 
12. Hampl R., Lapcik O., Starka L., ey. al. 7-hydroxydehydroepiandrosterne-a natural antiglucocorticoid and a candidate for steroid replacement therapy ?. Physiol. Res. 49 (Suppl. 1) : S107-S112, 2000.
 
13. Chalbot S., Morfin R. Dehydroepiandrosterone metabolites and their interactions in human. Drug Metabol. Drug Interact. 22 : 1-23, 2006.
PubMed
14. Weill-Engerer S., Akwa Y., et. al. In vitro metabolism of dehydroepiandrosterosterone (DHEA) to 7α-hydroxy-DHEA and Δ5-androsterone-3β, 17β-diol in specific regions of the aging brain from Altzheimer's and non-demented patients. Brain Res. 969 : 117-125, 2003.
 
15. Yau JLW., Rasmuson S., Sekl JR., et. al. DHEA 7-hydroxylase CYP7B : enrichment in primate hypocampus and functional depletion in Alzheimer's disease. Neuroscience 121 : 307-314, 2003.
 
16. Rupprecht R., Papadoulos V., Schumacher M., et. al. Translocator protein (18KDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nature Rev. Drug Discovery. 9 : 971-988, 2010.
 
17. Laurine E., Lafitte D., Verdier JM., et. al. Specific binding of dehydroepiandrosterone to the N terminus of the microtubule-associated protein MAP2. J. Biol. Chem. 278 : 29979-29986, 2003.
 
18. Harden ST., Glowacki J., LeBoff MS., et. al. Effects of age on serum dehydorepiandro-sterone sulfate, IGF-1 and IL-6 levels in women. Calcif. Tissue Int. 66 : 414-418, 2000.
 
19. Murialdo G., Barreca A., Polleri A., et. al. Relationships between cortisol. dehydroepi-androsterone sulfate and insulin-like growth factor-1 system in dementia. J. Endocrinol Invest. 24 : 139-146, 2001.
 
20. Luppi C., Fioravanti M., Solerte SB., et.al. Growth factors decrease in subjects with mild to moderate Alzheimer's disease (AD) : potential correction with dehydroepiandrosterone-sulfate (DHEAS). Arch. Gerontol. Geriatr. Suppl. 1 : 173-184, 2009.
 
21. Wolkowitz OM., Kramer JH., Roberts E., et. al. DHEA treatment, double-blind, placebo-controlled study. Neurology 60 : 1071-1076, 2003.
 
22. Yasuda S., Akishita M., Ouchi Y., et. al. Effects of dehydroepiandrosterone supple-mentation on cognitive function and activities of daily living in older women with mild to moderate cognitive impairment. Geriatr. Geront. Int. 10 : 280-287, 2010.
 
P.179 掲載の参考文献
1. Taniguchi S., Yanase T., Nawata H. et. al. The antiobesity of dehydroepiandrosterone in castrated obese or non-castrated obese Zucker male rats. Obesity Res. 3 : 639-643, 1995.
 
2. McNeils JC., Maolopoulos KN., Art W. et. al. Dehydroepiandrosterone exerts antigluco-corticoid action on human preadipocyte proliferation, differentiation and glucose uptake Am. J. Physiol. Endocrinol. Metab. 305 : E1134-E1144, 2013.
 
3. Bujalska IJ., Gatharole LL., Stewart PM., et. al. A novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. J. Endocrinol. 197 : 297-307, 2008.
 
4. Karbowska J., Kochan Z. Effects of DHEA on metabolic and endocrine functions of adipose tissue. Horm. Mol. Biol. Clin. Investig. 14 : 65-74, 2013.
PubMed
5. Aouadi M., Jager., Bost F., et. al. P38Map kinase activity is required for human primary adipocyte differentiation. FEBS Letters 581 : 5591-5596, 2007.
 
6. Engelman JA., Lisanti MP., Scherer PE., Specific inhibitor of p38 mitogen-activated protein kinase block 3T3-L1 adipogenesis. J. Biol. Chem. 273 : 32111-32120, 1998.
PubMed
7. Ashida K., Goto K., Nawata H., et. al. Dehydroepiandrosterone negatively regulates the p38 mitogen-activated protein kinase pathway by a novel mitogen-activated protein kinase phosphatase. Biochem. Biophy. Acta 1728 : 84-94, 2005.
 
8. Watanabe T., Ashida K., Nawata H., et. al. Dehydroepiandrosterone -enhanced duel specificity protein phosphatase (DDSP) prevents diet-induced and genetic obesity. Biochem. Biopys. Res. Comm. 468 : 196-201, 2015.
 
9. Fujioka K., Kajita K., Ishizuka T., et. al. Dehydroepiandrosterone reduces preadipocyte proliferation via androgen receptor. Am. J. Physiol. Endocrinol. Metab. 302 : E694-E704, 2012.
 
10. Fehar T., Bodragi L. A comparative study of steroid concentrations in human adipose tissue and the peripheral circulation. Clin. Chim. Acta 126 : 135-141, 1982.
 
11. Villareal DT., Hollanzy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men. A randomized conntorol study. J.A.M.A. 292 : 2243-2248,2004
 
12. Weiss EP., Vilareal DT., Holloszy JO. Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. Aging 3 : 533-542, 2011.
 
13. Yamada Y., Sekihara H., Nawata H., et. al. Changes in serum sex hormone profiles after short-term low dose administration of dehydroepiandrosteorne (DHEA) to young and elderly persons. Endocrine J. 54 : 153-162, 2007.
 
14. Aoki K., Saito T., Sekihara H., et. al. Dehydroepiandrosterone suppresses the elevated hepatic glucose-6 phosphatase and fructose-1,6-biphosphatase acitivities in C57BL/Ksj-db/db mice comparison with troglitasone. Diabetes 48 : 1579-1585, 1999.
 
15. Yamashita R., Saito T., Sekihara H., et. al. Effects of dehydroepiandrosterone on gluconeogenic enzymes and glucose uptake in human hepatoma cell line, HepG2. Endocr. J. 52 : 727-733, 2005.
 
16. Ishizuka T., Kajita K., Yasuda K., et. al. DHEA improves glucose uptake via activations of protein kinase C and phosphatidylinositol 3-kinase. Am. J. Physiol. 276 : E196-E204, 1999.
 
17. Perrini S., Natalicchio A., Giorgino F., et. al. Dehydorepiandrosterone stimulates glucose uptake in human and murine adipocytes by inducing GLUT1 and GLUT4 translocation to the plasma membrane. Diabetes 53 : 41-52, 2004.
 
18. Nakashima N., Haji M., Nawata H., et. al. Effect of dehydroepiandrosterone on glucose uptake in cultured human fibroblasts. Metabolism 44 : 543-548, 1995.
 
19. Nakashima N., Haji M., Nawata H., et. al. Effect of dehydroepiandrosterone on glucose uptake in cultured rat myoblasts. Horm. Metab. Res. 27 : 491-494, 1995.
 
20. Kimura M., Tanaka S., Sekihara H., et. al. Dehydroepiandrosterone decreses serum tumor necrosis factor-α and rstores insulin sensitivity : independent effect from secondary weight reduction in genetically obese Zucker fatty rats. Endocrinology 139 : 3249-3253, 1998.
 
21. Taniguchi S., Yanase T., Nawata H., et. al. Dehydroepiandrosterone markedly inhibited the accumulation of cholesterol ester in mouse J774-1 cells. Atherosclerosis 126 : 143-154, 1996.
 
22. Okamoto K. Relationship between dehydroepiandrosterone sulfate and serum lipid levels in Japanese men. J. Epidemiol. 6 : 63-67, 1996.
 
23. Kawano H., Yasue H., Ogawa H., et. al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J. Clin.Endocrinol. Metab. 88 : 3190-3195, 2003.
 
24. Jesse RL., Eich., Nestler JE., et. al. Dehydroepiandrosterone inhibits human platelet aggregation in vitro. Ann. N.Y. Acad. Sci. 774 : 281-290, 1995.
 
25. Bertoni A., Rastoldo A., Singaglia F., et. al. Dehydroepiandrosterone-sulfate inhibits thrombin-induced platelet aggregation. Steroids 77 : 260-268, 2012.
 
26. Fukui M., Kitagawa Y., Yoshikawa T., et. al. Association between albumin excretion and serum dehydroepiandrosterone sulfate concentration in male patients with type 2 diabetes. Diabetes Care 27 : 2893-2897, 2004.
 
27. Tehernof A., Labrie F. Review Dehydroepiandrosterone, obesity and cardiovascular disease risk : a review of human studies. Europ. J. Endocrinol. 151 : 1-14, 2004.
 
28. Ohlsson C., Labrie F., Tivesten A., et. al. Low serum levels of dehydroepiandrosterone sulfate predict all-cause and cardiovascular mortality in elderly Swedish men. J. Clin. Endocrinol. Metab. 95 : 4406-4414, 2010.
 
29. Jimenez MC., Sun Qi., Rexrode KM., et. al. Low dehydroepiandrosterone sulfate is associated with increased risk of ischemic stroke among women. Stoke 44 : 1784-1789, 2013
 
30. Komesaroff PA., Unravelling the enigma of dehydroepiandrosterone moving forward step by step. Endocrinology 149 : 886-888, 2008.
PubMed
31. Savineau JP., Marsen R., Eric D. Role of DHEA in cardiovascular diseases. Biochem Pharmacol. 85 : 718-726, 2013.
 
32. Liu D., Dillon JS. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Gai 2,3. J. Biol. Chem 277 : 21379-21388, 2002.
 
33. Liu D., Dillon JS. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells : evidence for a cell surface receptor. Steroids 69 : 279-289, 2004.
PubMed
34. Liu D., Iruthayanthan M., Dillon JS., et. al. Dehydroepiandrosterone stimulates endothelial proliferation and angiogenesis through extracellular signal-regulated kinase 1/2 mediated mechanisms. Endocrinology 149 : 889-898, 2008.
 
35. Charalampopulos I., Alexaki VI., Lizarididis I., et. al. G protein-associated specific membrane binding sites mediate the neuroprotective effect of dehydroepiandrosterone FASEB J. 20 : 577-579, 2006.
 
36. Chen J., Xu L., Huang C. DHEA inhibits vascular remodeling following arterial injury : a possible role in suppression of inflammation and oxidative stress derived from vascular smooth muscle cells. Mol. Cell. Biochem. 388 : 75 -84, 2014.
 
P.190 掲載の参考文献
1. Shimizu N., Yoshikawa N., Tanaka H., et. al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab. 13 : 170-182, 2011.
 
2. Ceci R., Duranti G., Sabatini S., et.al. Skeletal muscle differentiation : role of dehydroepiandrosterone sulfate. Horm. Metab. Res. 43 : 702-707, 2011.
PubMed
3. Sugino M., Ohsawa N., Shinoda K., et. al. A pilot study of dehydroepiandrosterone sulfate in myotonic dystrophy. Neurology 51 : 586-589, 1998.
 
4. Tsuji K., Furuhata D., Ohsawa N., et. al. Specific binding and effects of dehydroepi-androsterone sulfate (DHEA-S) on skeletal muscle cells : possible implication for DHEA-S replacement therapy in patients with myotonic dystrophy. Life Sci. 65 : 17-26, 1999.
 
5. Sato K., Iemitsu M. Exercise and sex steroid hormones in skeletal muscle. J. Steroid. Biochem. Mol. Biol. 145 : 200-205, 2015.
PubMed
6. Baker WL., Karen S., Kenny AM. Effects of dehydroepiandrosterone on muscle and physical function in older adults : a systemic review. J. Am. Geriatr. Soc. 59 : 997-1002, 2011.
 
7. Kenny AM., Boxer RS., Burlesson JA., et. al. Dehydroepiandrosterone combined with exercise improves muscle strength and physical function in frail older women. J. Am. Geriatr. Soc. 58 : 1707-1714, 2010.
 
8. Swiecicka A., Lunt M., Giwercman A., et. al. Non androgenic anabolic hormones predict risk of frailty : europian male ageing study perspective date. J. Clin. Endocrinol. Metab. 102 : 2798-2806, 2017.
 
9. Goncharova N. D., Marenin V. Y., Oganyan T. E. Aging of the hypothalamic-pituitary adrenal axis in nonhuman primates with depression-like and aggressive behavior. Aging 2 : 854-866, 2010.
PubMed
10. Gupta D., Morley J. E. Hypothalamic-pituitary-adrenal (HPA) axis and aging. Compr. Physiol. 4 : 1495-1510, 2014.
PubMed
P.193 掲載の参考文献
1. Straub RH., Miller LE., Zietz B., et. al. Cytokine and hormones as a possible links between endocrinosenescence and immunosenescence. J. Neuroimmunol. 109 : 10-15, 2009.
 
2. Chen CCG., Parker Jr. CR. Adrenal androgen and the immune system. Seminars in reproductive medicine 22 : 369-377, 2004.
 
3. Radford DJ., Wanf K., Lord JM., et. al. Dehydroepiandrosterone sulfate directly activates protein kinase C-β to increase human neutrophil superoxide generation. Mol. Endocrinol. 24 : 813-821, 2010.
 
4. Straub RH., Konecna L., Lang B., et. al. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro : possible link between endocrinosenescence and immunosenescence. J. Clin. Endocrinol. Meatab. 83 : 2012-2017, 1998.
 
5. Sawalha AH., Kovats S. Dehydroepiandrosterone in systemic lupus erythematosus. Curr. Rheumatol. Rep. 10 : 286-291, 2008.
PubMed
6. Racchi M., Buoso E., Corsini E., et. al. Role of hormones in the regulation of RACK1 expression as a singnaling checkpoint in immunosenescence. Int. J. Mol. Sci. 18 : 1453-1465, 2017.
 
P.197 掲載の参考文献
1. Prough RA., Clark BJ., Klinge CM. Novel mechanism for DHEA action : Review. J. Mol. Endocrinol. 56 : R139-R155, 2016.
PubMed
2. Traish AM., Kang HP., Guay AT., et. al. Dehydroepiandrosterone (DHEA)-A precursor steroid or an active hormone in human physiology. J. Sex. Med. 8 : 2960-2988, 2011.
PubMed
3. Webb SJ., Geoghegan TE., Miller KM., et. al. The biological actions of dehydroepi-androsterone involves multiple receptors. Drug Metabol. Rev. 38 : 89-116, 2006.
 
4. Niro S., Hennebert O., Morfin R. New insights into the protective effects of DHEA. Horm. Mol. Biol. Clin. Invest. 4 : 489-498, 2010.
 
5. Maninger N., Wolkowitz O. N., Mellon S. H. et al. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Front. Neuroendocrinol. 30 : 65-91, 2009.
 
P.198 掲載の参考文献
1. Labrie F. All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause. J. Steroid. Biochem. Mol. Biol. 145 : 133-138, 2015.
PubMed
2. Labrie F. DHEA, important source of sex steroids in men and even more m women. Prog. Brain. Res. 182 : 97-137, 2010. Elsevier BV.
 
P.200 掲載の参考文献
1. Okabe T., Haji M., Nawata H., et. al. Up-regulation of high-affinity dehydroepiandro-steorne binding activity by dehydroepiandrosterone in activated human T lymphocytes. J. Clin .Endocrinol. Metab. 80 : 2993-2996, 1995.
 
2. Miekle AW., Dorchuck RW., Daynes RA., et. al. The presence of dehydroepiandro-sterone specific receptor binding in murine T cells. J. Steorid. Biochem. Mol. Biol. 42 : 293-304, 1992
 
3. Hampl R., Lapcik O., Starka L., et. al. 7-Hydroxydehydroepiandrosterone-a natural antiglucocorticoid and a candidate for steroid replacement therapy? Physiol. Res. 49 : S107-S112, 2000.
 
4. Le Mee S., Hennebert O., Morfin R., et. al. 7β-Hydroxyepiandrosterone-mediated regulation of the prostaglandin synthesis pathway in human peripheral blood monocytes. Steroids 73 : 1148-1159, 2008.
 
5. Chen F., Knecht K., Mojena M., et. al. Direct agonist/antagonist function of dehydro-epiandrosterone. Endocrinology 146 : 4568-4576, 2005.
 
P.203 掲載の参考文献
1. Strac DS., Jembrek MJ., Periacic D., et. al. Modulation of recombinant GABAA receptor by neurosteroid dehydroepiandrosterone sulfate. Pharmacology 89 : 89-163, 2012.
 
2. Twede V., Tartaglia AM., Bamber BA., et. al. The neurosteorids dehydroepiandro-sterone sulfate and pregnenolone sulfate inhibit the UNC-49GABA receptor through a common set of residues. Mol. Pharmacol, 72 : 1322-1329, 2007.
 
3. Braat S., Kooy RF. Perspective. The GABAA receptor as a therapeutic target for neurodevelopmental disorders. Neuron 86 : 1119-1130, 2015.
 
4. Regan MC., Romero-Hernandez A., Furukawa H. A structural biology. perspective on NMDAr receptor. pharmacology and function. Curr. Opin. Struct. Biol. 33 : 68-75, 2015.
PubMed
5. Waterhouse RN., Chang RC., Collier TL., et. al. In vitro and in vivo binding of neuroactive steroids to the Sigma-1 receptor as measured with the position emission tomography radioligand [18F] FPS. Synapse 61 : 540-546, 2007.
 
6. Hayashi T., Su T-T. Sigma-1 receptor ligands : Potential in the treatment of neuro-psychiatric disorders. CNS Drugs. 18 : 269-284, 2004.
 
7. Hayashi T., Su T-P. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca (++) signaling and cell survival. Cell 131 : 596-610, 2007.
PubMed
8. Su T-P., Hayashi T., Ruoho AE. The sigma-1 receptor chaperones as an inter-organelle signaling modulator. Trends Pharmacol. Sci. 31 : 557-566, 2010.
PubMed
9. Hashimoto K. Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication. J. Pharmacol. Sci. 127 : 6-9, 2015.
PubMed
10. Pediaditakis I., Iliopoulos I., Gravanis A., et. al. Dehydroepiandrosterone : an ancestral ligand of neurotrophin receptors. Endocrinology 156 : 16-23, 2015.
 
11. Lazaridis I., Charalampopoulos I., Gravanis A., et. al. Neurosteoid dehydroepiandro-sterone interacts with nerve growth factor (NGF) receptors, preventing neural apoptosis. PLoS Biol. 9 : e100-1051, 2011.
 
12. Prossnitz ER., Barton M. Estrogen biology : new insights into GPER function and clinical opportunities. Mol. Cell Endocrinol. 389 : 71-83, 2014.
PubMed
13. Teng Y., Litchfield LM., Klinge CM., et. al. Dehydroepiandrosterone induces mi-R21 transcription in HepG2 cells through estrogen receptor β and androgen receptor. Mol. Cell Endocrinol. 392 : 23-36, 2014.
 
14. Teng Y., Raddle BN., Klinge CM., et. al. Dehydroepiandrosteorne activation of G-protein-coupled estrogen receptor rapidly stimulates microRNA-21 transcription in human hepatocellular carcinoma cells. J. Biol. Chem. 290 : 15799-15811, 2015.
 
15. Liang X., Glowcki J., Zhou S., et. al. Dehydroepiandrosterone stimulation of osteo-blastogenesis in human MSCs requires IGF-1 signaling. J. Cell Biochem. 117 : 1769-1774, 2016.
 

第10章 超高齢社会とDHEAS

P.210 掲載の参考文献
1. Kroll J. Dehydroepiandrosterone, molecular chaperones and the epigenetics of primate longevity. Rejuvenation Res. 18 : 341-346, 2015.
PubMed
2. Kroll J. Molecular chaperones and the epigenetics of longevity and cancer resistance. Ann. N. Y. Acad. Sci. 1100 : 75-83, 2007.
PubMed
3. Cutler RG. Evolution of human longevity : a critical overview. Mech. Ageing Dev. 9 : 337-354, 1979.
PubMed
4. Kenyon CJ. The genetics of ageing. Review. Nature 464 : 504-512, 2010.
PubMed
5. Willcox BJ., Tranah GJ., Donion TA., et. al. The FoxO3 gene and cause-specific mortality Aging Cell 15 : 617-624, 2016.
 
6. Roth GS., Lane MA., Metter EJ., et. al. Biomarkers of caloric restriction may predict longevity in human. Science 297 : 811, 2002.
 
7. Mattison JA., Roth GS., Anderson RM. Caloric restriction improves health and survival of rhesus monkey. Nature Commun. Article 8 : 1-12, 2017.
 
P.214 掲載の参考文献
1. Mushid A., Eguchi T., Calderwood SK. Stress proteins in aging and life span. International J. Hyperthermia 29 : 442-447, 2013.
 
2. Akerfelt M., Morimoto RI., Sistonen L. Heat shock factors : Integrator of cell stress, development and life span. Nat. Rev. Mol. Cell Biol. 11 : 545-555, 2010.
PubMed
3. Calderwood, Mushid A., Prince T. The shock of aging : molecular chaperones and the heat shock response in longevity and aging-A mini-review. Gerontology 29 : 550-558, 2009.
 
4. Soti C., Csermely P. Molecular chaperones and the aging process. Biogerontology 1 : 225-233, 2000.
PubMed
5. Njenini R., Bautmans I., Mets T., et. al. Circulating heat shock protein 70 in health. aging and disease BMC Immunol. 12 : 12-24, 2011.
 
6. Uitenboggard M., Baxter KK., Chiaramello A. NeuroD6 genomic signature bridging neuronal differentiation to survival via the molecular chaperone network. J. Neurosci. Res. 88 : 33-54, 2010.
 
7. Lee S-J, Lee S-H, Park B-J., et. al. Estrogen prevents senescence through induction of WRN, Werner syndrome protein. Hormone Res. Pediatr. 74 : 33-40, 2010
 
8. Summers DW., Douglas PM., Cyr. DM., et. al. Polypeptide transfer form Hsp 40 to Hsp 70 molecular chaperones. Trends Biochem. Sci. 34 : 230-233, 2009.
 
9. Smith DF., Toft DO. Minireview : the intersection of steroid receptor with molecular chaperones : observation and questions. Mol. Endocrinol. 22 : 2229-2238, 2008.
PubMed
10. Zannas AS., Wiechmann T., Binder EB., et. al. Gene-stress-epigenetic regulation of FKBP5 : clinical and translational implication. Neuropsychopharmacol. Review 41 : 261-274, 2016.
 
P.221 掲載の参考文献
1. Kroll J. Correlation of plasma cortisol levels, chaperone expression and mammalian longevity : a review of published data. Biogerontology 11 : 495-499, 2010.
PubMed
2. Lupien SL. Cortisol levels during human aging predict hippocampal atrophy and memory deficit. Nature Nuerosci. 1 : 69-73, 1998.
 
3. Lupien SL., McEwen BS., Heim C., et. al. Effects of stress throughout the life span on the brain, behavior and cognition. Nature. Review Neurosci. 10 : 434-445, 2009.
 
P.222 掲載の参考文献
1. Zhai G., Vandenput L., Wallaschofski H., et. al. Eight common genetic variant associated with serum DHEAS levels suggest a key role in ageing mechanisms. PLoS Genet. 7 : 1-10, 2011.
 
2. Vandenput L., Ohlson C. Genome-wide association studies on serum sex steroid levels. Mol. Cellular Endocrinol. 382 : 758-766, 2014.
 
3. Calvo E., Leu-The V., Labrie F. Pangenomic changes induced by DHEA in the skin of postmenopausal women. J. Steroid Biochem. Mol. Biol. 112 : 186-193, 2008.
 
4. Lee JS., Ward WO., Corton JC., et. al. Hepatic xenobiotic metabolizing enzyme and transporter gene expression through the life stages of the mouse. PLoS One 1-11, 2011.
 
5. Charlton M., Lindor K., et.al. Low circulating levels of dehydroepiandrosterone in hepatologically advanced nonalcoholic fatty liver disease. Hepatology 47 : 484-492, 2008.
 
P.227 掲載の参考文献
1. Enomoto M., Adachi H., Imaizumi T., et. al. Serum dehydroepiandrosterone sulfate levels predict longevity in men : 27-year follow up study in a community-based cohort study (Tanushimaru study). J. Am. Geriatr. Soc. 56 : 994-998, 2008.
 
2. Yanase T., Muta K., Nawata H. Serum concentration of dehydroepiandrosterone sulfate (DHEA-S) in oldest old Japanese women correlate with cognitive activity rather than acitivities of daily living. Geriatr.Gerontol. Int. 6 : 194-198, 2006.
 
P.229 掲載の参考文献
1. Redman L., MR avussin E. Endocrine alterations in response to caloric restriction in humans. Mol. Cel. Endocrinol. 299 : 129-136, 2009.
 
2. Lettieri-Barbato D., Giovannetti E., Aquilano K. Effects of dietary restriction on adipose mass and biomarkers of healthy aging in human. A ging 8 : 3341-3355, 2016.
 
3. Willcox BJ., Willicox DR., Suzuki M., et. al. Caloric restriction. the traditional Okinawa diet and healthy aging. Ann. NY. Acad. Sci. 1114 : 434-455, 2007
 
4. Yanagita I., Yanase.T., Nawata H., et. al. Low glycated hemoglobin level is associated with severity of frailty in Japanese elderly diabetes patients. J. Diabetes Invest. 9 : 419-425, 2018.
 
5. Abdelhafiz AH., Sinclair AJ. Low HbA1c and increased mortality risk is frailty a confounding factor. Aging and Disease 6 : 262-270, 2015.
PubMed
6. Zaslavsky O., Walker RL., Larson EB., et. al. Glucose levels and risk of frailty. J. Gerontol A. Biol. Sci. Med. Sci. 71 : 1223-1229, 2016.
 
7. Selvin E.. Steffes MW., Brancati FL., et.al. Glycated hemoglobin. diabetes and cardio-vascular risk in nondiabetic adult. N. Engl. J. Med. 362 : 800-811, 2010.
 
8. Minihane AM., Vinoy S., Calder PC., et.al. Low-grade inflammation, diet composition and health : current research evidence and its translation. Br. J.Nutr.114 : 999-1012, 2015.
PubMed
P.235 掲載の参考文献
1. Samaras N., Samaras D., Philippe J. et. al. A review of age-related dehydroepiandro-sterone decline and its association with well-known geriatric syndrome : is treatment beneficial? Rejuvenation Res, 16 : 285-194, 2013.
 
2. Arlt W. The approach to the adult newly diagnosed adrenal insufficiency. J. Clin. Endo criol. Metab. 94 : 1059-1067, 2009.
 
3. Schmidt PJ., Rubin DR., et. al. Dehydroepiandrosterone monotherapy is midlife onset major and minor depression. Arch.Gen. Psychiatry. 62 : 154-162, 2006
 
4. Parasrampuria J., Petesch R. Quality control of dehydroepiandrosterone dietary supplement products. JAMA 280 : 1565, 1998.
PubMed
5. 名和田新 (2001) 「DHEAは高齢化社会の福音となるか」『ばんぶう』5月号, 72-72頁.
 

第11章 生活習慣病の予防

P.240 掲載の参考文献
1. 名和田新他 (2007) 『これでわかる特定健診制度』じほう.
 
1. Hiroo Imura. Life course care and preemptive approach to non-communicable disease. Proc. Jpn. Acad. Ser. B. 89 : 462-473, 2013.
PubMed
2. 井村裕夫 (2012) 『日本の未来を拓く医療-治療医学から先制医療へ』診断と治療社.
 
P.242 掲載の参考文献
1. 名和田新 (2012) 「未来につなぐ英知を拓く-1. 公立大学法人化後の飛躍」『福岡県立大学開学20周年記念誌-ひらく夢 筑豊に育まれて』 23-28頁.
 
2. 日野原重明 (2015) 「チーム医療における、看護師の新しい役割」井村裕夫編『医と人間』岩波書店, 161-172頁.
 

書評

最近チェックした商品履歴

Loading...